-
Mashup Score: 13Liquid biopsy in colorectal cancer – the time has come? - 10 month(s) ago
Recent findings from studies confirm the promises of ctDNA in this setting, but unsanswered questions still remain about timing and methodology
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advanced genetic testing largely inaccessible to cancer patients - 10 month(s) ago
An ESMO study shows that precision oncology is out of reach for the majority of patients
Source: Daily ReporterCategories: Hem/Oncs, Latest HeadlinesTweet-
In Europe, precision oncology is out of reach for most patients, with costs of technologies and reimbursement policies acting as major barriers https://t.co/td351ECVfp https://t.co/csUKuvKK3N
-
-
Mashup Score: 5Advanced genetic testing largely inaccessible to cancer patients - 10 month(s) ago
An ESMO study shows that precision oncology is out of reach for the majority of patients
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An ESMO study revealed that advanced genetic testing, is largely inaccessible to #CancerPatients across Europe. ESMO can play a pivotal role to build a framework for #PrecisionMedicine that reaches all patients who can benefit from it. 📌https://t.co/No59OkYSsm https://t.co/dh73UpGpfL
-
-
Mashup Score: 0On the horizon of translational research - 10 month(s) ago
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are major areas of interest leading to more patient-centric approaches in cancer care
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What’s on the horizon of #TranslationalResearch? Tumour agnostic targeted agents, dynamic study designs and genomically enriched trials are reshaping the landscape of #PrecisionOncology 👉https://t.co/kKBBYTtGe3 @ElenaGarralda https://t.co/K7YmDTUywg
-
-
Mashup Score: 0Green prescribing may limit the environmental impact of oncology - 11 month(s) ago
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ESMO supports @UNEP’s #WorldEnvironmentDay. @JalvingHilde Chair of ESMO Climate Change Task Force calls for guidance on “green” prescribing that may limit the #environmental impact of #oncology, since #sustainability is key to #CancerCare. 👉https://t.co/pLwWQsxoiN https://t.co/iIlwIwuXRs
-
-
Mashup Score: 0Early-phase data from targeting HER3 with ADC are encouraging - 12 month(s) ago
Some studies suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative and triple-negative breast cancers
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast23: Suggesting data from ICARUS-BREAST01 and SOLTI TOT-HER3 trials show the preliminary activity of patritumab–deruxtecan in patients with HR+/HER2- #BreastCancer and #TNBC. Read this feature with @JavierCortesMD 👉https://t.co/JTjynl0Rgh https://t.co/UfUf5Mu7p2
-
-
Mashup Score: 9Does AI hold the future of early cancer detection? - 12 month(s) ago
Technology promises to improve understanding of cancer risk and lesion biology, but clear regulation is urged
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast23: Does AI hold the future of early #CancerDetection? David Crosby, in his keynote lecture: AI and machine learning will play an integral part in assessing cancer risk, with some potential implications in screening 👉 https://t.co/5aEaWZpRjE @CR_UK https://t.co/FJkTBqSrtb
-
-
Mashup Score: 0PROs data from key trial results in metastatic breast cancer, - 12 month(s) ago
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Extended safety & PROs data presented at #ESMOBreast23 from three studies confirm the role of T-DXd and elacestrant in #bcmet 📌https://t.co/ZpRbCtYcs7 @dimeglio_anto @GustaveRoussy https://t.co/bzAKRVdt3t
-
-
Mashup Score: 0Challenging past dogma in breast cancer research - 12 month(s) ago
Recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What’s next in #BreastCancer research? In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz highlights the need to challenge accepted paradigms to progress clinical research. 📌https://t.co/Nog0LvlnrJ #ESMOBreast23 @UCLAHealth https://t.co/EepltGQcWg
-
-
Mashup Score: 0Breast cancer leads the way in ADC therapy - 12 month(s) ago
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast23: Would the lessons learned from the use of second-generation ADCs in #BreastCancer direct treatment in other solid tumours? @CarmenCriscit took a deep dive into the rationale for testing these beyond #BreastCancer 👉https://t.co/lnd1t5lfmA https://t.co/U6AiFtP33p
-
#LiquidBiopsy has emerged as a powerful tool for identifying MRD and early detection especially in #CRC. Recent findings from studies confirm the promises of #ctDNA in this setting, but unanswered questions still remain about timing & methodology. 📌https://t.co/z806wa9p0D https://t.co/zsjXCE3oUR